Our Partners
We have established a consortium of care, a network of the best of the best in the industry. Our partners are critical to our non-profit model and to our patients. They say it takes a village, this is our village. We have partners in all areas of drug discovery, drug development and manufacturing. Each partner provides us and our patients support, which in turn allows us to reduce our cost per patient, enabling us to reach even more patients. Please support our partners.
A Growing Network of Partnerships
Click a company logo to see how our partners are supporting nano-rare
Genomic
Sequencing
Children’s Mercy Kansas City
Children’s Mercy Kansas City is a leading independent children’s health organization dedicated to holistic care, translational research, breakthrough innovation, and educating the next generation of caregivers.
Covance by Labcorp
Covance’s partnership helps support our discovery and development efforts to provide experimental medicines for nano-rare patients.
GeneDX
GeneDx’s partnership helps to understand the genetic cause of nano-rare mutations. They are the leader in delivering clinical genomic answers to an ever-increasing community of patients, families and healthcare providers.
Illumina
Illumina supports our nano-rare patients by sequencing patient genomes so that each patients unique mutation can be identified and understood. Illumina’s goal is to goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago.
WSG Provides Hope to Patients with Nano-rare Diseases
PacBio
PacBio supports our nano-rare patients by sequencing patient genomes so that each patient’s unique mutation can be identified and understood. PacBio uses genomics to better human health.
Biotechnology/Pharmaceutical Companies
Ionis
Ionis is a founding donor of n-Lorem and has been a strong supporter in our efforts to bring hope and potential help to nano-rare patients.
Biogen
Biogen is a founding donor of n-Lorem. Biogen is a neuroscience pioneer committted to providing innovative treatment options to patients around the globe.
Alexion
Alexion shares our mission to support the discovery and development of personalized experimental medicine for nano-rare individuals.
Alnylam
Alnylam is a proud partner that reinforces efforts to reach more nano-rare patients where an RNAi directed approach would be most useful. Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options.
Coming Together for the Nano-rare
Takeda
Takeda is a generous donor of n-Lorem. Takeda is focused on creating better health for people and a brighter future for the world. Takeda aims to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Coming Soon
UltraGenyx
Ultragenyx focuses on development of innovative medicines to move the rare-disease community forward and a generous donor of n-Lorem.
Shifting Mindsets to Expedite Rare Treatments
n-Lorem Foundation and Ultragenyx United in Efforts to Help Nano-rare Patients
Manufacturing
.
ChemGenes Corporation
ChemGenes Corporation provides significant manufacturing support of n-Lorem and our patients.
Cytiva
Cytiva is a worldwide provider of technologies and services that advances the development, manufacture, and delivery of therapeutics. Cytiva is a generous supporter of n-Lorem and our nano-rare patients.
No Patient Left Behind – n-Lorem Foundation
Nitto Avecia
Nitto Avecia is a donor and partner that provides n-Lorem manufacturing support through its contributions of active pharmaceutical ingredients (API) and drug product for individualized ASO medicines. They have helped advance oligonucleotide innovation for over 25 years through development and production.
Hongene
Hongene is a donor and partner that supports n-Lorem’s efforts by providing compounds essential for developing ASO medicines, to help offset the costs of developing personalized experimental ASO medicines for nano-rare patients.
Integrated DNA Technologies
Integrated DNA Technologies is a global genomics solutions provider that provides significant discounts to support n-Lorem’s optimal ASO discovery efforts.
RNA-Targeted
Drug Discovery
La Jolla Labs
La Jolla Lab’s strong partnership with n-Lorem helps support our discovery efforts for nano-rare patients. La Jolla Labs leverages their high-throughput screening technology to design and screen for RNA-targeting ASOs.
Foundations
.
Anonymous Donor
Target ALS
Target ALS is a non-profit organization that envisions a world where everyone with ALS lives.
Everybody Lives
Fostering Collaboration to Fight ALS
Conrad Prebys Foundation
The Conrad Prebys Foundation creates an inclusive, equitable, and dynamic future for all San Diegans by advancing excellence and shared opportunity through investments in groundbreaking institutions, ideas, and people.
SolveFSHD
Solve FSHD’s purpose is to Solve FSHD2 while further benefiting FSHD1 by removing barriers and accelerating drug development for FSHD.
Wolverine Foundation
The Wolverine Foundation serves to advance research and discover novel therapeutic approaches to treat the neuro-developmental disease caused by genetic variations in the gene MAPK8IP3.
Pre-Clinical
Toxicology CROs
Charles River
Charles River Labs provides support for a substantial amount of pre-clinical toxicity studies, and data collection to support regulatory filing.
Free for Life: The Story of n-Lorem
Greenfield Pathology Services
Greenfield Pathology Services is a generous partner of n-Lorem, whose pathologists are donating time and expertise in support of n-Lorem’s development efforts.
Korea Institute of Toxicology
The Korean Institute of Toxicology (KIT), a world class, government-funded research institute, provides substantial research support by conducting pre-clinical toxicity studies.
KreaMedica
KreaMedica provides support by conducting pre-clinical tolerability studies.
Sterile Fill Product
.
Argonaut
Argonaut Manufacturing Services is our partner in providing personalized experimental ASOs to nano-rare patients.
Nitto Avecia Pharma Services
Nitto Avecia is a donor and partner that provides n-Lorem manufacturing support through its contributions of active pharmaceutical ingredients (API) and drug product for individualized ASO medicines. They have helped advance oligonucleotide innovation for over 25 years through development and production.
Schott Pharma
Schott Pharma is a generous supporter of n-Lorem providing vials for drug sterile-fill and finish.
Clinical
Management
Parexel
Parexel’s partnership provides clinical operations, real-world data solutions, medical and regulatory expertise and innovative clinical research tools that significantly enhance and streamline n-Lorem’s experimental medicines development efforts. They are one of the world’s leading global clinical research organizations.
CROs and Their Role for Nano-rare
Access to Appropriately
Characterized Patients and Investigators
Undiagnosed Diseases Network
The Undiagnosed Diseases Network (UDN) is a research study that is funded by the National Institutes of Health Common Fund. Its purpose is to bring together clinical and research experts from across the United States to solve the most challenging medical mysteries using advanced technologies.
A Diagnostic Odyssey: The UDN and n-Lorem’s Roles
Other personalized medical centers
Data Partners
.
Across Healthcare
Across Healthcare’s partnership provides n-Lorem with innovative technology solutions.
Unipr
Unipr’s partnership provides n-Lorem integrated project, program, and portfolio management capapabilities. Unipr is the world most advanced project software.
Bits and Bytes Help Streamline Bench to Bedside
Disease Focused
.
ASXL3
FSHD2
MAPK8IP3
Silence ALS
Ionis is a founding donor of n-Lorem and has been a strong supporter in our efforts to bring hope and potential help to nano-rare patients.
n-Lorem Foundation and Columbia University Establish Silence ALS Initiative
Other
.
COMBINEDBrain
Combined Brain is a consortium devoted to speeding the path to clinical treatments for people with severe rare genetic neurodevelopmental disorders.
Cooley
Cooley shares our mission to support the discovery and development of personalized experimental medicine to nano-rare individuals.
Cowen
Cowen is an independent, entrepreneurial-minded financial services firm that shares our mission to support the discovery and development of personalized experimental medicine to nano-rare individuals.
J. Wood Capital Advisors
J. Wood Capital Advisors is a generous donor that shares our mission to support the discovery and development of personalized experimental medicine for nano-rare individuals. They are an advisory and brokerage firm that empowers companies and organizations to raise capital in a smarter, more efficient manner with focused and unbiased advise.
Stifel
Stifel shares our mission to support the discovery and development of personalized experimental medicine for nano-rare individuals.
Sysnav Healthcare
Sysnav Healthcare has supported the n-Lorem Foundation during a single-patient study involving a KIF1A patient treated with an optimal ASO discovered and developed by n-Lorem. Sysnav’s leading digital health technology, Syde, continuously monitors patient function and physical activity throughout the treatment evaluation period. The data collected by Syde provides more precise and quicker potential evidence of the therapeutic efficacy.
We cannot do
this alone
Together we are changing the world—
one patient at a time
We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.
We need your support
Join us on our Corps of Discovery of the mind and heart. Help us bring hope and potential help to nano-rare patients today. For free, for life.
